Study of effectiveness of mifepristone for glioma cell line growth suppression

British Journal of Neurosurgery

Volumn 26, Issue 3, 2012, Pages 336-339

  Ramaswamy, Raghu ^a   Ashton, Katherine ^a   Lea, Robert ^b   Roberts, Philip ^b   Davis, Charles H ^a   Golash, Aprajay ^a   Dawson, Timothy ^a  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Cell lines; Glioblastoma multiforme; Growth suppression; Mifepristone; Progesterone receptors

Indexed keywords

DEXAMETHASONE; MIFEPRISTONE; PROGESTERONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; PRIMARY TUMOR; PRIORITY JOURNAL; THERAPY EFFECT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MIFEPRISTONE;

EID: 84861651764     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2011.629696     Document Type: Article

References (28)

1. Pinski J, Halmos G, Shirahige Y, Wittliff J, Schally AV. Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486 * . J Clin Endocrinol Metab 1993;77:1388-93.
2. Gonz á lez-Agüero G, Gutiérrez AA, Gonz á lez-Espinosa D, Solano JD, Morales R, Gonz á lez-Arenas A, Cabrera-Muñoz E, Camacho- Arroyo I. Progesterone eff ects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine 2007;32:129-35. Epub 2007 Nov 15.
3. M aiuri F, De Caro Mdel B, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007;82:63-8. Epub 2007 Jan 17.
4. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997;86:113-20.
5. O verdiek A, Winner U, Mayatepek E, Rosenbaum T. Schwann cells from human neurofi bromas show increased proliferation rates under the infl uence of progesterone. Pediatr Res 2008;64:40-3.
6. A shok PW, Wagaarachchi PT, Templeton A. The antiprogestogen mifepristone: a review. Curr Med Chem- Immun Endoc & Metab Agents 2002;2:71-90.
7. L ammert M, Mautner VF, Kluwe L. Do hormonal contraceptives stimulate growth of neurofi bromas? A survey on 59 NF1 patients. BMC Cancer 2005;5:16.
8. W right DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, et al.. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007;49:391-402, 402.e1-2. Epub 2006 Sep 29.
9. Y ao XL, Liu J, Lee E, Ling GS, McCabe JT. Progesterone diff erentially regulates pro- and anti-apoptotic gene expression in cerebral cortex following traumatic brain injury in rats. J Neurotrauma 2005;22:656-68.
10. O ' C onnor CA, Cernak I, Johnson F, Vink R. Eff ects of progesterone on neurologic and morphologic outcome following diff use traumatic brain injury in rats. Exp Neurol 2007;205:145-53. Epub 2007 Feb
11. T sutsui K. Biosynthesis and organizing action of neurosteroids in the developing Purkinje cell. Cerebellum 2006;5:89-96.
12. S tein DG, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008 51 ;164-72. Epub 2007 Jun
13. Jones NC, Constantin D, Prior MJ, Morris PG, Marsden CA, Murphy S. The neuroprotective eff ect of progesterone after traumatic brain injury in male mice is independent of both the infl ammatory response and growth factor expression. Eur J Neurosci 2005;21:1547-54.
14. Quadros PS, Goldstein AY, De Vries GJ, Wagner CK. Regulation of sex diff erences in progesterone receptor expression in the medial preoptic nucleus of postnatal rats. J Neuroendocrinol 2002;14: 761-7.
15. Gonz á lez-Agüero G, Ondarza R, Gamboa-Domínguez A, Cerbón MA, Camacho-Arroyo I. Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull 2001;56:43-8.
16. Och W, Mariak Z, Kopeć J, Smó? ka M, Koziorowski M. Correlation of expression of progesterone receptors with histopathological type and grade of malignancy of cerebral neoplasms. Neurol Neurochir Pol 2001;35 Suppl 5:110-18.
17. P ravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006;105:163-73.
18. Claus EB, Park PJ, Carroll R, Chan J, Black PM. Specifi c genes expressed in association with progesterone receptors in meningioma. Cancer Res 2008;68:314-22.
19. V erheijen FM, Sprong M, Jacobs HM, Donker GH, Amelink GJ, Th ijssen JH, Blankenstein MA. Progesterone receptor isoform expression in human meningiomas. Eur J Cancer 2001;37: 1488-95.
20. G upta V, Su YS, Wang W, Kardosh A, Liebes LF, Hofman FM, Schönthal AH, Chen TC. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus 2006;20:E20.
21. Wei MX, Liu JM, Gadal F, Yi P, Liu J, Crepin M. Sodium phenylacetate (NaPa) improves the TAM eff ect on glioblastoma experimental tumors by inducing cell growth arrest and apoptosis. Anticancer Res 2007;27:953-8.
22. P uchner MJ, Köppen JA, Zapf S, Knabbe C, Westphal M. The infl uence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo fi ndings. Anticancer Res 2002;22:45-51.
23. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J, Nicholson S, et al.. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997;3:1109-15.
24. I noue T, Akahira J-I, Suzuki T, Darnel AD, Kaneko C, Takahashi K, Hatori M, et al.. Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 2002;87:5325-31.
25. B lankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Th ijssen JH. Occurrence, regulation, and signifi cance of progesterone receptors in human meningioma. Steroids 2000;65 :795-800.
26. G runberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-33.
27. G runberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-6.
28. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992;55: 486-90.